• 1
    Jemal A,Siegel R,Ward E,Hao Y,Xu J,Murray T,Thun MJ. Cancer statistics, 2008. CA Cancer J Clin 2008; 58: 7196.
  • 2
    Itamochi H,Kigawa J,Terakawa N. Mechanisms of chemoresistance and poor prognosis in ovarian clear cell carcinoma. Cancer Sci 2008; 99: 6538.
  • 3
    Jacobs IJ,Menon U. Progress and challenges in screening for early detection of ovarian cancer. Mol Cell Proteomics 2004; 3: 35566.
  • 4
    Rapkiewicz AV,Espina V,Petricoin EF,III,Liotta LA. Biomarkers of ovarian tumours. Eur J Cancer 2004; 40: 260412.
  • 5
    Sugiyama T,Kamura T,Kigawa J,Terakawa N,Kikuchi Y,Kita T,Suzuki M,Sato I,Taguchi K. Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy. Cancer 2000; 88: 25849.
  • 6
    Pectasides D,Pectasides E,Psyrri A,Economopoulos T. Treatment issues in clear cell carcinoma of the ovary: a different entity? Oncologist 2006; 11: 108994.
  • 7
    Kaetzel MA,Hazarika P,Dedman JR. Differential tissue expression of three 35-kDa annexin calcium-dependent phospholipid-binding proteins. J Biol Chem 1989; 264: 1446370.
  • 8
    Zanotti G,Malpeli G,Gliubich F,Folli C,Stoppini M,Olivi L,Savoia A,Berni R. Structure of the trigonal crystal form of bovine annexin IV. Biochem J 1998; 329: 1016.
  • 9
    Kaetzel MA,Mo YD,Mealy TR,Campos B,Bergsma-Schutter W,Brisson A,Dedman JR,Seaton BA. Phosphorylation mutants elucidate the mechanism of annexin IV-mediated membrane aggregation. Biochemistry 2001; 40: 41929.
  • 10
    Hill WG,Kaetzel MA,Kishore BK,Dedman JR,Zeidel ML. Annexin A4 reduces water and proton permeability of model membranes but does not alter aquaporin 2-mediated water transport in isolated endosomes. J Gen Physiol 2003; 121: 41325.
  • 11
    Sohma H,Creutz CE,Gasa S,Ohkawa H,Akino T,Kuroki Y. Differential lipid specificities of the repeated domains of annexin IV. Biochim Biophys Acta 2001; 1546: 20515.
  • 12
    Piljic A,Schultz C. Annexin A4 self-association modulates general membrane protein mobility in living cells. Mol Biol Cell 2006; 17: 331828.
  • 13
    Kaetzel MA,Chan HC,Dubinsky WP,Dedman JR,Nelson DJ. A role for annexin IV in epithelial cell function. Inhibition of calcium-activated chloride conductance. J Biol Chem 1994; 269: 5297302.
  • 14
    Han EK,Tahir SK,Cherian SP,Collins N,Ng SC. Modulation of paclitaxel resistance by annexin IV in human cancer cell lines. Br J Cancer 2000; 83: 838.
  • 15
    Morita A,Miyagi E,Yasumitsu H,Kawasaki H,Hirano H,Hirahara F. Proteomic search for potential diagnostic markers and therapeutic targets for ovarian clear cell adenocarcinoma. Proteomics 2006; 6: 588090.
  • 16
    Shevchenko A,Wilm M,Vorm O,Mann M. Mass spectrometric sequencing of proteins silver-stained polyacrylamide gels. Anal Chem 1996; 68: 8508.
  • 17
    Ikuta K,Takemura K,Sasaki K,Kihara M,Nishimura M,Ueda N,Naito S,Lee E,Shimizu E,Yamauchi A. Expression of multidrug resistance proteins and accumulation of cisplatin in human non-small cell lung cancer cells. Biol Pharm Bull 2005; 28: 70712.
  • 18
    Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial. Lancet 2002; 360: 50515.
  • 19
    Tammela J,Geisler JP,Eskew PN,Jr,Geisler HE. Clear cell carcinoma of the ovary: poor prognosis compared to serous carcinoma. Eur J Gynaecol Oncol 1998; 19: 43840.
  • 20
    O'Brien ME,Schofield JB,Tan S,Fryatt I,Fisher C,Wiltshaw E. Clear cell epithelial ovarian cancer (mesonephroid): bad prognosis only in early stages. Gynecol Oncol 1993; 49: 2504.
  • 21
    Raynal P,Pollard HB,Srivastava M Cell cycle and post-transcriptional regulation of annexin expression in IMR-90 human fibroblasts. Biochem J 1997; 322: 36571.